Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE-CRC: S-531011 + Fruquintinib +/- Pembrolizumab in MSS/pMMR Colorectal Cancer
NCT07591597Phase 2Not yet recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of S-531011 in colorectal cancer (CRC), sponsored by National Cancer Center Hospital East. Planned start May 2026; status: not yet recruiting.
02
Drugs
S-531011
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07591597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591597.